(Reuters) - The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin device, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.
The FDA said the device offers a new treatment option for patients with Type 1 diabetes.
"Today's approval broadens the options available for delivering mealtime insulin in the overall management of patients with diabetes who require it to control blood sugar levels," Dr. Jean-Marc Guettier, director of the FDA's endocrinology division, said in a statement.
Help employers find you! Check out all the jobs and post your resume.
